Pharma BD Deal Intelligence
Akorn paid ~$433M for VersaPharm in 2014; the acquirer itself collapsed into two Chapter bankruptcies (2020, then Chapter 7 liquidation in 2023), wiping out equity and shuttering all US operations.
Full analysis, sources & comparables →Increases presence in the highly attractive niche dermatology market... Adds $90-100 million in annual revenues... Immediately accretive to earnings...…
Pharmaceutical Technology highlighted the strategic complementarity with the recent Hi-Tech acquisition, framing VersaPharm as enabling Akorn to double…
The FTC required divestitures because VersaPharm was one of only three FDA-approved generic injectable rifampin suppliers, evidencing concentrated antitrust…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Akorn agreed to acquire VPI Holdings, parent of VersaPharm, for $440M in cash, adding 11 ANDAs filed with FDA plus a 20+ product pipeline in dermatology, TB and hemophilia. Closed August 12, 2014 with FTC-mandated divestitures.
Akorn paid ~$433M for VersaPharm in 2014; the acquirer itself collapsed into two Chapter bankruptcies (2020, then Chapter 7 liquidation in 2023), wiping out equity and shuttering all US operations.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Akorn, Inc. / VPI Holdings Corp. (VersaPharm Incorporated) (this deal) | 2014 | $440M | 14 |
| Akorn, Inc. / Hi-Tech Pharmacal Co. Inc. | 2013 | $640M | 28 |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
← Browse all deals · How we score deals
More: 2014 deals · Dermatology deals